Upcoming Events & Webinars
Join our events and webinars to meet experts, build collaborations and be the first to see new product releases.
Upcoming Webinars
-
2024-06-13T05:00:00Z
Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, decentralized and small labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security, adopting NGS poses challenges for labs with limited staff and infrastructure.
To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar, learn about QCI Secondary Analysis, an agnostic, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.
In this webinar, attendees will learn how QCI Secondary Analysis:
- Streamlines analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment.
- Ensures the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements.
- Directly connects to QCI Interpret for an integrated and automated FASTQ-to-report workflow with limited hands-on time.
Neha Jalan, PhD, Professional Services Solutions Manager -
2024-06-13T11:00:00Z
Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, decentralized and small labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security, adopting NGS poses challenges for labs with limited staff and infrastructure.
To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar, learn about QCI Secondary Analysis, an agnostic, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.
In this webinar, attendees will learn how QCI Secondary Analysis:
- Streamlines analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment.
- Ensures the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements.
- Directly connects to QCI Interpret for an integrated and automated FASTQ-to-report workflow with limited hands-on time.
Neha Jalan, PhD, Professional Services Solutions Manager -
2024-06-13T07:30:00Z
Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, decentralized and small labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security, adopting NGS poses challenges for labs with limited staff and infrastructure.
To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar, learn about QCI Secondary Analysis, an agnostic, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.
In this webinar, attendees will learn how QCI Secondary Analysis:
- Streamlines analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment.
- Ensures the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements.
- Directly connects to QCI Interpret for an integrated and automated FASTQ-to-report workflow with limited hands-on time.
Neha Jalan, PhD, Professional Services Solutions Manager -
2024-06-13T17:00:00Z
Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, decentralized and small labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security, adopting NGS poses challenges for labs with limited staff and infrastructure.
To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar, learn about QCI Secondary Analysis, an agnostic, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.
In this webinar, attendees will learn how QCI Secondary Analysis:
- Streamlines analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment.
- Ensures the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements.
- Directly connects to QCI Interpret for an integrated and automated FASTQ-to-report workflow with limited hands-on time.
Neha Jalan, PhD, Professional Services Solutions Manager
-
2024-06-25T17:00:00ZJoin us for one or two 40-minute talks. Each presentation will have a 15-minute live Q&A at the end. To start, Dr. Maria A. Bautista will present her findings on using hybrid capture to sequence viral pathogens. Stay with us or join one hour after the start of the session for Dr. Aaron Bivins will compare dPCR systems for microbial tracking.
Talk 1: Unlocking viral diversity in wastewater: Using hybrid capture for enhanced human viral pathogen detection
Dr. Maria A. Bautista, University of Calgary
Time: 1 p.m. EDT/10 a.m. PDT
Duration: 1 hour
Wastewater surveillance is a promising tool for detecting and tracking viral pathogens in municipal wastewater, providing valuable insights into population health and disease risk. Despite this potential, genomic sequencing of pathogens is challenging due to their relatively low abundance and the high background of nucleic acid from humans, bacteria and other viruses. We have successfully used hybrid-capture panels to enhance the recovery of viral pathogenic sequences from wastewater. Here, I discuss increasing the output and detection of viruses of interest from wastewater using QIAGEN QIAseq xHYB hybrid capture panels in combination with ribosomal RNA removal.
Talk 2: Comparing dPCR systems for microbial source tracking in surface waters
Dr. Aaron Bivins, Louisiana State University
Time: 2 p.m. EDT/11 a.m. PDT
Duration: 1 hour
Wastewater surveillance has accelerated the adoption of digital PCR (dPCR) in various formats for quantifying molecular targets. Public health-related water microbiology requires analytical sensitivity, resilience to inhibition, and precise quantification, which makes dPCR an especially promising tool. Nonetheless, most standardized molecular methods for assessing water quality employ quantitative PCR (qPCR) for molecular measurements. We adapted qPCR assays from three U.S. EPA Methods (1696: HF183/BacR287; 1609.1 Entero1a; Draft Method C: EC23S857) to dPCR format and compared their performance for detecting and quantifying targets in positive controls (SRM 2917) and environmental samples (n=10) on two different dPCR platforms (QIAcuity [QIAGEN], Absolute Q [Themo Fischer Scientific]). We analyzed filter triplicates (x3) and dPCR technical replicates (x2) on both platforms for all environmental samples. The analytical sensitivity varied slightly between the platforms for each assay. Intra-class correlation coefficients (ICC) indicate excellent quantitative agreement (ICC > 0.96) between the QIAcuity and Absolute Q across positive control materials for all three assays. Overall, we found the QIAcuity and Absolute Q platforms yielded reasonably similar qualitative and quantitative results. However, we found there were important operational characteristics to consider when selecting a platform for routine water quality monitoring.Dr. Maria A. Bautista, Senior Research Associate - Geomicrobiology and 1 more -
2024-06-25T13:00:00Z
In this webinar, we will explore the synergy between the QIAwave Kits, the eco-friendlier versions of our standard sample preparation kits for genomic DNA, plasmid DNA and RNA isolation, and the QIAcube Connect system.
This webinar will also delve into the broader benefits that this pairing brings to the nucleic acid purification process. This tandem will not only improve the sustainability of your research but also enhance workflow efficiency and optimization. In this session, we will also provide practical insights into using the QIAwave kits and the benefits of the packaging concept, share new dedicated QIAcube protocols, and provide new means of how we can support you in harnessing the full potential of your research.
Inga Irle, Associate Director, Marketing and Product Management and 1 more
-
2024-06-26T07:00:00ZJoin us for one or two 40-minute talks. Each presentation will have a 15-minute live Q&A at the end. To start, Dr. Maria A. Bautista will present her findings on using hybrid capture to sequence viral pathogens. Stay with us or join one hour after the start of the session for Dr. Aaron Bivins will compare dPCR systems for microbial tracking.
Talk 1: Unlocking viral diversity in wastewater: Using hybrid capture for enhanced human viral pathogen detection
Dr. Maria A. Bautista, University of Calgary
Time: 1 p.m. EDT/10 a.m. PDT
Duration: 1 hour
Wastewater surveillance is a promising tool for detecting and tracking viral pathogens in municipal wastewater, providing valuable insights into population health and disease risk. Despite this potential, genomic sequencing of pathogens is challenging due to their relatively low abundance and the high background of nucleic acid from humans, bacteria and other viruses. We have successfully used hybrid-capture panels to enhance the recovery of viral pathogenic sequences from wastewater. Here, I discuss increasing the output and detection of viruses of interest from wastewater using QIAGEN QIAseq xHYB hybrid capture panels in combination with ribosomal RNA removal.
Talk 2: Comparing dPCR systems for microbial source tracking in surface waters
Dr. Aaron Bivins, Louisiana State University
Time: 2 p.m. EDT/11 a.m. PDT
Duration: 1 hour
Wastewater surveillance has accelerated the adoption of digital PCR (dPCR) in various formats for quantifying molecular targets. Public health-related water microbiology requires analytical sensitivity, resilience to inhibition, and precise quantification, which makes dPCR an especially promising tool. Nonetheless, most standardized molecular methods for assessing water quality employ quantitative PCR (qPCR) for molecular measurements. We adapted qPCR assays from three U.S. EPA Methods (1696: HF183/BacR287; 1609.1 Entero1a; Draft Method C: EC23S857) to dPCR format and compared their performance for detecting and quantifying targets in positive controls (SRM 2917) and environmental samples (n=10) on two different dPCR platforms (QIAcuity [QIAGEN], Absolute Q [Themo Fischer Scientific]). We analyzed filter triplicates (x3) and dPCR technical replicates (x2) on both platforms for all environmental samples. The analytical sensitivity varied slightly between the platforms for each assay. Intra-class correlation coefficients (ICC) indicate excellent quantitative agreement (ICC > 0.96) between the QIAcuity and Absolute Q across positive control materials for all three assays. Overall, we found the QIAcuity and Absolute Q platforms yielded reasonably similar qualitative and quantitative results. However, we found there were important operational characteristics to consider when selecting a platform for routine water quality monitoring.Dr. Maria A. Bautista, Senior Research Associate - Geomicrobiology and 1 more
-
2024-06-27T05:00:00Z
In this webinar, we will explore the synergy between the QIAwave Kits, the eco-friendlier versions of our standard sample preparation kits for genomic DNA, plasmid DNA and RNA isolation, and the QIAcube Connect system.
This webinar will also delve into the broader benefits that this pairing brings to the nucleic acid purification process. This tandem will not only improve the sustainability of your research but also enhance workflow efficiency and optimization. In this session, we will also provide practical insights into using the QIAwave kits and the benefits of the packaging concept, share new dedicated QIAcube protocols, and provide new means of how we can support you in harnessing the full potential of your research.
Inga Irle, Associate Director, Marketing and Product Management and 1 more -
2024-06-27T16:00:00Z
In this webinar, we will explore the synergy between the QIAwave Kits, the eco-friendlier versions of our standard sample preparation kits for genomic DNA, plasmid DNA and RNA isolation, and the QIAcube Connect system.
This webinar will also delve into the broader benefits that this pairing brings to the nucleic acid purification process. This tandem will not only improve the sustainability of your research but also enhance workflow efficiency and optimization. In this session, we will also provide practical insights into using the QIAwave kits and the benefits of the packaging concept, share new dedicated QIAcube protocols, and provide new means of how we can support you in harnessing the full potential of your research.
Inga Irle, Associate Director, Marketing and Product Management and 1 more